



EVENT GUIDE

Cancer Crosslinks 2021 - A Digital Event

Thursday, January 21, 2021, 12pm - 4pm (CET)

Theme:

Driving the Translation of Scientific Insights Into Clinical Practice:
From “Nice to Know” to “Need to Implement”

Cancer Crosslinks 2021 is a digital event gathering a distinguished panel of international experts presenting recent progress in precision treatment and cancer immunotherapy.

Table of Contents

Speakers.....	2
Moderators & Panelists.....	4
General Information.....	5
Technical Assistance.....	6
Virtual Space Information.....	7
Program - 13th Cancer Crosslinks 2021.....	8

To learn more about Cancer Crosslinks, please visit: cancercrosslinks.com

For more information, please contact
Jutta Heix: jh@oslocancercluster.no or Charlotte Homme: cwh@oslocancercluster.no.

Supported by:



Speakers - Cancer Crosslinks 2021



Ahmad Awada, Professor, Head of the Oncology Medicine Department
Jules Bordet Cancer Institute Brussels, Belgium

Professor Ahmad Awada was born in Lebanon and studied Medicine at the Université Libre de Bruxelles (ULB), Belgium. He specialised in Internal Medicine and Medical Oncology at Jules Bordet Institute, in Brussels, until 1992. During his specialisation, he also followed trainings in the clinical development of new anticancer drugs. As a research fellow, he stayed in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development). He focused on the clinical development of new anticancer agents from cytotoxic and endocrine agents to molecular-targeted agents and more recently immunotherapies.

In 1994, Dr. Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute, Brussels. Since April 2005, he is the Head of the Medical Oncology Clinic. In addition, and from 1st March 2011, Dr. Awada was held Associate Head of Medicine Department. More recently, on the 7th of July 2017, Dr. Awada was appointed Head of Oncology Medicine Department. He has an important clinical activity in the treatment of solid tumors and in particular breast cancer. Dr. Awada took an active part in the development of new drugs in several solid tumors, some of them already widely used.

Dr. Awada is a member of several international scientific societies (ASCO, EORTC, ESMO), co-founder of Oncodistinct network for oncology research and Professor of Clinical Medicine and Medical Oncology at the Université Libre de Bruxelles. Dr. Awada is author or co-author of 32 book chapters and, 322 articles in international publications.

Photo/Bio: Speaker



Jérôme Galon, Director of Research at INSERM, Head of INSERM laboratory for Integrative Cancer Immunology, Cordeliers Research Center, Paris, France

Dr. Jérôme Galon is first class Director of Research at INSERM (French National Institute of Health and Medical Research) and head of an INSERM laboratory (INSERM UMRS1138, Integrative Cancer Immunology) at the Cordeliers Research Center in Paris, France. Dr. Jérôme Galon is the co-founder of the company, HalioDx, and is the Chairman of its scientific council. He is associate Director and co-founder of European Academy of Tumor Immunology (EATI), Board Director of Society for Immunotherapy of Cancer (SITC, USA), member of AAI, SFI, and AACR. He also serves on numerous advisory panels.

Dr. Galon was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France). He holds a Ph.D. degree in Immunology (Jussieu University, Paris, France, 1996). Between 1997 and 2001, he worked at the NIH (National Institute of Health, Bethesda, USA) on functional genomics, bioinformatics and immunology on fundamental and clinical research. Since his full-tenured position at INSERM in 2001, he directs interdisciplinary research programs.

Dr. Jérôme Galon has made important contributions to medical research through his groundbreaking work in the fields of immunology and cancer research. His contributions have been recognized with numerous awards. He received the prestigious William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (Cancer Research Institute, New York, USA), Award from the National Academy of Science, and Award from the National Academy of Medicine, fellow Award for Research Excellence at NIH (USA), Awards from the French foundation, from the Medical Research Foundation, from the French Society of Immunology (Jacques Oudin Award). He gave the prestigious Annual B. Benacerraf Lecture in Immunology (Harvard, USA, 2014). He is best known for his works on comprehensive analysis of the tumor-microenvironment in human cancer and bioinformatics, and for the discovery that the adaptive immune reaction within the tumor was a better predictor of survival than traditional staging based on cancer's size and spread. He defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. Dr. Galon has published over 150 papers in top-tier scientific journals, and delivered over 250 invited lectures internationally.

Photo/INSERM, Bio./Speaker

Speakers - Cancer Crosslinks 2021



Marcela Maus, Assistant Professor, Medicine, Harvard Medical School
Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, USA

Dr. Marcela Maus is the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center and an Attending Physician in the Bone Marrow Transplant and Cell Therapy division of Oncology at the Massachusetts General Hospital. Dr. Maus is an Assistant Professor at Harvard Medical School, an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard. Dr. Maus is a translational physician-scientist in the field of immunology, particularly as it relates to cancer. Her lab focuses on the design, generation, and use of innovative forms of immune cell engineering, including chimeric antigen receptors. Her laboratory investigates basic mechanisms of human immunology to design and test novel immune-based therapeutic interventions in vitro, in mouse models, and in patients. Dr. Maus received her S.B. from the Massachusetts Institute of Technology, and her M.D. and Ph.D. degrees from the University of Pennsylvania. Dr. Maus trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering, and is board-certified in these three disciplines. Her laboratory research training focused on gene and cell therapies, and occurred in the laboratories of Dr. Katherine High, Dr. Michel Sadelain, and Dr. Carl June.

Photo/Bio: Speaker



Andrew Sewell, Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute, Cardiff University, UK

Andrew Sewell initially trained in Chemistry before undertaking a PhD in Genetics at the University of Liverpool (1991). He then embarked on postdoctoral training, and was promoted to the faculty, at the University of Utah; the spiritual home of the human genome project. He returned to the UK in 1995 to research how the HIV virus evades the human immune system at the Nuffield Department of Medicine, University of Oxford where he became a Wellcome Trust Senior Fellow. He relocated to Cardiff University in 2006 and became a Wellcome Trust Senior Investigator and has been continuously Wellcome-funded for over 24 years. His research group focuses on T-cell ligands and the receptors that recognise them ($\alpha\beta$ TCR, $\gamma\delta$ TCR, CD4 and CD8). Most of his recent work is based around understanding the basic biology of antigen recognition by human T-cells using two novel pipelines for the discovery of new T-cell targets. These technologies are being applied to autoimmune disease, immunity to infection, transplant tolerance and to discover the ligands recognised by T-cells in extreme cancer survivors and during successful cancer immunotherapy. Professor Sewell has amassed over 200 scientific publications that have been cited over 10,000 times in total.

Photo: cardiff.ac.uk, Bio: tcells.org



Emile Voest, Professor of Medical Oncology, Medical Director Netherlands Cancer Institute, Netherlands

Emile Voest is medical oncologist, senior group leader at the Netherlands Cancer Institute, senior scientist of the Onco Institute, and translational scientist. He is the current director of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. His laboratory group is devoted to bringing precision medicine to patients and is focused on mechanistic studies of tumor biology and applying computational science and genomics to better understand how tumors respond to certain treatments. The results from these studies are subsequently tested for their value in patients. These translational approaches are performed across tumor types with emphasis on epithelial tumors. His research is in the area of precision medicine and consists of large scale genomic sequencing of patients with metastatic cancer, the development of primary cultures of tumors for ex vivo testing (including tumor organoids) and the use of these cultures to improve drug development and to determine which treatment is best for a specific patient.

Photo/Bio: Speaker

Moderators & Panelists - Cancer Crosslinks 2021

Profiles for the moderators and panelists can be found in the Digital Event Space.

Moderator, Session 1



Jon Amund Kyte, Head, Department of Experimental Cancer Treatment, Oslo University Hospital Comprehensive Cancer Center, Oslo

Panelists, Session 1



Emiel A.M. Janssen, Professor, University of Stavanger, Dept. of Pathology, Stavanger University Hospital, Stavanger



Nina Jebesen, Associate Professor, Dept. of Clinical Science, Haukeland University Hospital, Bergen



Anne Hansen Ree, Professor of Oncology, Akershus University Hospital, University of Oslo



Halfdan Sørbye, Professor, Dept. of Oncology, Haukeland University Hospital, Bergen

Moderator, Session 2



Johanna Olweus, Professor, University of Oslo, Head of Department of Cancer Immunology, Oslo University Hospital

Panelists, Session 2



Ingerid Weum Abrahamsen, Senior Consultant Hematology, Dept. of Hematology, Oslo University Hospital



Jochen Buechner, Senior Consultant Pediatric Hematology & Oncology, Oslo University Hospital

Moderator, Session 3



Sigrid Bratlie, Special Advisor, Norwegian Cancer Society

Panelists, Session 3



Ali Areffard, Disease Area Specialist Immuno-Oncology, Bristol Myers Squibb



Siri Børø, Medical Specialist Oncology, Merck



Åslaug Helland, Professor, Head of Research Division of Cancer Medicine, Oslo University Hospital

Photos: Speakers

General Information



How do I access the virtual event - Cancer Crosslinks 2021?

Enter the website via <https://eventmobi.com/cancercrosslinks2021>. Enter the email address you used to register and create a password. You should now be able to access the Cancer Crosslinks Virtual Event. Information about preferred browsers is on page 6.

May I access the event platform prior to the January 21, 2021 event?

The platform will be accessible as of January 14, 2021. You are welcome to visit the event platform to familiarize yourself with the menu options, functions, and edit your profile (ex: you can upload a profile photo and add information and contact details). This information will be visible for all registered participants.

Do I need a camera and/or microphone?

A camera and microphone are not required to attend the live sessions, however you need a computer with internet connection and speakers to follow the virtual event. Access to a keyboard is needed in case you would like to make a comment in the “chat” section and to ask a question via the “Q&A” section (complementing the livestream).


Will the event be available to view after January 21, 2021?

Recorded sessions from the event will be available via the Digital Event Platform until February 21, 2021, so please keep the link and your password to access the content until February 21, 2021. Please visit cancercrosslinks.com for updates.

What are some of the functions available on the Cancer Crosslinks 2021 platform?

Functions:

- Watch all live sessions
- Post questions and comments for the speakers – moderators will address the incoming questions during the panel discussions
- Connect with other participants via the chat function (visible to everyone) or send individual messages by clicking on the attendee name.
- Edit your profile, upload a profile photo, and/or add information and contact details.
- Once you have logged into the Cancer Crosslinks Virtual Event, there is a menu of options in the top left corner:



Technical Assistance



Which browser should I use?

Most common browsers work well with the event platform: Firefox 20 and higher, Safari 6.0 and higher, Chrome 19 and higher, Edge 40 and higher. Using the event platform via Internet Explorer is not recommended.

If I cannot see the livestream - what should I do?

Please try to refresh the page. Make sure your adblocker is deactivated. You may try switching to another browser – see above.

If I cannot hear anything - what should I do?


Please check the sound settings on your device to see if the correct source is selected. Please check that your audio/loudspeakers/headphones/video is on.

Additional questions?

Please contact support chat via the virtual space. See below for instructions:

Step 1)

Click on the question mark on the top right corner



Step 2)

This opens a chat window at the bottom right of the screen.

A screenshot of a chat window. It contains three input fields: 'Name' with the placeholder 'XXX', 'Email' with the placeholder 'my@mail.com', and 'Message (optional)'. At the bottom right of the window is a dark blue button labeled 'Start chat'.

Virtual Space Information



IMPORTANT

Access information to the Cancer Crosslinks 2021 Virtual Event has been/will be sent to all registrants on January 14 & 20, 2021. Registrants are encouraged to log-in PRIOR to January 21, 2021 to test the functions.

How can I edit my profile?

Click on profile photo in the upper right corner and go on “Edit profile”. You can upload a new image, add information about yourself, your organization, as well as share your social media details.

How can I contact other participants?

Click on Attendees, Speakers or Panelist in the sidebar - select a person, click on the name, then select “send a message”. This will start a private conversation with the person contacted.

Where can I find my private messages?

You can access all private messages that have been sent or received in the event platform by clicking on the “bell” next to the profile photo (upper right corner of the screen).

How can I ask questions during the sessions?

You can ask questions during the live sessions by submitting a question in the Q&A function.

What is an ‘announcement’?

Announcements are general notifications from Cancer Crosslinks 2021. To re-read the latest announcements, click on the “bell” next to the profile photo (upper right corner of the screen), and then click on the latest announcement.

Where are the recorded sessions?

You can access the recorded session under “Recordings” in the sidebar. Recordings of the sessions will be uploaded after the event and participants will be notified once the videos are accessible.

How long can I access the Virtual Space after the event?

The virtual space will be available until February 21, 2021. Additional information about the availability of materials from the event will be posted at cancercrosslinks.com.

Program - 13th Cancer Crosslinks 2021

Thursday, January 21, 2021, presented as a digital meeting with opportunities to engage.

Driving the Translation of Scientific Insights Into Clinical Practice: From “Nice to Know” to “Need to Implement”	
11:45 – 12:00	Log-in to Digital Meeting Platform
12:00 – 12:10	Opening and Welcome, <i>Jutta Heix, Oslo Cancer Cluster and Jon Amund Kyte, Oslo University Hospital</i>
12:10 – 12:35	Opening Keynote: Utilizing Targeted Therapy and Immunotherapy Earlier – What is the Rationale and How Cancer Patients Benefit. <i>Ahmad Awada, Professor, Head of the Oncology Medicine Department, Jules Bordet Cancer Institute Brussels, Belgium</i>
12:35 – 12:55	Keynote: The Interplay Between Tumor Evolution and Tumor Immunology: Implications on Progression and Treatment <i>Jérôme Galon, Director of Research at INSERM, Head of INSERM laboratory for Integrative Cancer Immunology, Cordeliers Research Center, Paris, France</i>
12:55 – 13:30	Panel Discussion: How Can We Drive the Translation of Scientific Insights Into Clinical Practice? What is “Nice to Know”? Where is the “Need to Implement”? <i>Moderator: Jon Amund Kyte, Head, Department of Experimental Cancer Treatment, Oslo University Hospital Comprehensive Cancer Center</i>
13:30 – 13:45	COFFEE BREAK & VIRTUAL NETWORKING OPPORTUNITIES
13:45 – 13:50	Introduction Cell Therapy Session, <i>Johanna Olweus, Oslo University Hospital</i>
13:50 – 14:15	Keynote: Translating Next Generation Cell Therapies into the Clinic: What are Hurdles and How Can We Overcome These? <i>Marcela Maus, Assistant Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital</i>
14:15 – 14:35	Keynote: New T-cell Receptors and Targets by Dissection of Successful Cancer Immunotherapy <i>Andrew Sewell, Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute, Cardiff University, UK</i>
14:35 – 15:00	Panel Discussion with Q&A <i>Moderator: Johanna Olweus, Professor, University of Oslo and Head of Department of Cancer Immunology, Oslo University Hospital</i>
15:00 – 15:15	COFFEE BREAK & VIRTUAL NETWORKING OPPORTUNITIES
	Introduction, <i>Sigrid Bratlie, Norwegian Cancer Society</i>
15:15 – 15:35	Keynote: Bringing Precision Medicine to Patients: Lessons Learned From DRUP Trial and the Way Forward <i>Emile Voest, Professor of Medical Oncology, Medical Director Netherlands Cancer Institute</i>
15:35 – 16:00	Panel Discussion: Precision Cancer Treatment - Opportunities and Challenges for Next-Generation Trials and Clinical Implementation <i>Moderator: Sigrid Bratlie, Special Advisor Norwegian Cancer Society</i>
16:00 – 16:30	VIRTUAL NETWORKING